Neuronetics, Inc. (NASDAQ: STIM) reported an insider sale on March 19, 2026, when Executive Vice President, Chief Legal Officer and Chief Strategy Officer William Andrew Macan sold 16,005 shares of common stock for approximately $21,446. The shares were transacted at prices ranging from $1.20 to $1.48, and the company's stock is trading at $1.46 with a market capitalization of $101 million.
The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission. According to the filing footnote, the trades were non-discretionary and executed to satisfy tax withholding obligations arising from the vesting of performance restricted stock units (PRSUs). After the transaction, Macan directly holds 897,270 shares of Neuronetics.
Financial and operational context
Neuronetics faces ongoing financial challenges, including a reported loss per share of $0.59 over the past twelve months. In its fourth-quarter 2025 report the company posted revenue of $41.8 million, exceeding the consensus forecast of $40.66 million and representing a 2.73% positive surprise. However, earnings per share came in at -$0.10 versus an expected -$0.09, an 11.11% negative surprise.
Among sell-side developments, Canaccord adjusted its price target on Neuronetics from $7.00 down to $3.00 while maintaining a Buy rating, noting that the fourth-quarter results and the company's guidance were in line with expectations. Separately, the company announced a leadership change, naming Dan Reuvers as its new chief executive officer. Neuronetics also reported being operationally cash flow positive in the second quarter, a detail highlighted in recent company disclosures.
Analysis and additional notes
An InvestingPro analysis cited within company commentary characterizes Neuronetics as slightly undervalued at current levels and notes that more in-depth research and reports are available to investors seeking to evaluate STIM's investment profile. The Form 4 filing and the footnote clarifying the tax-driven nature of the sale establish that the disposition was associated with routine award vesting rather than discretionary trading.
Investors monitoring Neuronetics will weigh the combination of a modest revenue beat, an EPS miss, a lowered price target from a prominent analyst, recent leadership change, and the company's reported operational cash flow positivity. The insider sale documented on March 19, 2026, is explicitly attributed in regulatory filings to tax-withholding requirements on vested performance awards.
Key takeaways
- Company insider William Andrew Macan sold 16,005 shares on March 19, 2026, for approximately $21,446 at prices between $1.20 and $1.48.
- The sale was non-discretionary and intended to satisfy tax withholding related to vested performance restricted stock units, per the Form 4 footnote.
- Neuronetics reported Q4 2025 revenue of $41.8 million (above the $40.66 million forecast) but recorded EPS of -$0.10 versus an expected -$0.09; leadership and cash flow updates were also disclosed.
Risks and uncertainties
- Continued net losses - the company reported a loss per share of $0.59 over the last twelve months, reflecting ongoing profitability pressures.
- Analyst valuation changes - Canaccord lowered its price target from $7.00 to $3.00, signaling revised near-term valuation expectations despite maintaining a Buy rating.
- Operational variability - while the company reported operational cash flow positivity in the second quarter, quarterly results can vary and Q4 2025 included an EPS miss relative to estimates.
This report is based solely on information disclosed in the company's SEC filing and the company's reported quarterly results and guidance. No additional assumptions or external commentary have been introduced beyond those disclosures.